Aclidinium —Almirall’s recently approved drug for COPD in US and Europe— will be one of the drugs rolled-out in Canada, where the Aclidinium respiratory franchise will be co-promoted with Forest. Almirall's net sales in the first half of 2012 were 374 million Euros (12.3% less than in 2011) but are in line with the company expectations, primarily due to legislative reforms in Spain and competition in some generic products.
Las ventas netas de Almirall el primer semestre de 2012 fueros de 374 millones de euros (un 12,3% menos que en 2011) y están en línea con las previsiones de la compañía, principalmente debido a las reformas legislativas en España y la competencia de genéricos en algunos productos.